Skip to main content
editorial
. 2018 Nov 6;9(87):35721–35722. doi: 10.18632/oncotarget.26291

Figure 1. The effect of JAK inhibitors on GvHD is demonstrated by overall survival of allo-HSCT recipient mice (B6 to Balb/c).

Figure 1

An in vivo administration of JAK1- or JAK2-specific inhibitors reduces GvHD. However, BARI and RUX, balanced JAK1/JAK2 inhibitors, are the most potent in GvHD prevention. The mean overall survival of vehicle control groups is 5%.